leadf
logo-loader
viewMatinas BioPharma

Full interview: Matinas BioPharma says Vascepa label expansion is 'ideal for the [Omega 3] class to kick off'

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) CEO Jerome Jabbour tells Proactive he's pleased the FDA is giving 'an early holiday gift' in the form of its approval for Amarin Corporation's (NASDAQ:AMRN) fish oil-derived drug Vascepa, now approved to prevent heart attacks and strokes in people who are at high cardiovascular risk.

Jabbour says the Vascepa label expansion is 'ideal for the [Omega 3] class to kick off,' and beneficial to patients, giving them greater access to a drug that can fight cardiovascular disease.

Quick facts: Matinas BioPharma

Price: 1.085 USD

NYSE:MTNB
Market: NYSE
Market Cap: $216.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Matinas BioPharma named herein, including the promotion by the Company of Matinas BioPharma in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Matinas BioPharma to begin dosing HIV patients with...

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) CEO Jerome Jabbour tells Proactive it will begin a Part 2 study of MAT2203 for the treatment of HIV patients with cryptococcal meningitis. Jabbour explains how the New Jersey-based company will begin dosing its first patient in the...

on 02/24/2020

2 min read